Clinical Trials for Solid Tumors
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors. Click here to learn more.
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II.
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions. Click here to learn more.
Molecular Analysis for Therapy Choice (MATCH). Click here to learn more.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion. Click here to learn more.
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumor. Click here to learn more.
A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors. Click here to learn more.
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors. Click here to learn more.
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors. Click here to learn more.
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. Click here to learn more.
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations. Click here to learn more.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). Click here to learn more.
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Click here to learn more.